Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

188 Clinical Updates found
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials
10 Trials and Growing: A Progress Update on the Thoracic Surgical Oncology Group Clinical Trials
The Thoracic Surgery Oncology Group (TSOG) is a joint initiative between the American Association for Thoracic Surgery and the Fiona & Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center (MSK).
urologic surgeon Jose Flores, MD, MHA
ED Drugs Do Not Increase Risk of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
A new study by investigators at Memorial Sloan Kettering Cancer Center (MSK) found no evidence of an increased risk of biochemical recurrence with any PDE5 inhibitor use or duration in the first year following radical prostatectomy.
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes
Rectal Cancer Response to Total Neoadjuvant Therapy Predicts Organ Preservation and Survival Outcomes
The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).
MSK Kids 2023: Six Key Areas of Cancer Research and Clinical Advances
MSK Kids 2023: Six Key Areas of Cancer Research and Clinical Advances
Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.
Dr. Cy Wilkins, Dr. Jae Park, Dr. Karthik Nath, Dr. Alina Markova, and Dr. Roni Shouval presented research related to managing and reducing treatment-related toxicities at the 2023 ASH meeting.
MSK ASH 2023 Insights: Managing and Reducing Treatment-Related Toxicities
Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023.
Photo of the bispecific antibody CD20xCD3 in action against a Lymphoma cell
MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies as First-Line Therapies for Patients with Follicular and B Cell Lymphoma
Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma and glofitamab (glofit) for patients with relapsed or refractory diffuse B cell lymphoma (DLBCL) or large B cell lymphoma (LBCL) treated with two or more prior lines of therapy.
MSK Researchers Report Advances for Gastric Cancer, Breast Cancer, Head and Neck Cancer, and More at ESMO Congress 2023
MSK Researchers Report Advances for Gastric Cancer, Breast Cancer, Head and Neck Cancer, and More at ESMO Congress 2023
Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their cutting-edge research at the European Society of Medical Oncology (ESMO) Congress 2023, held in Madrid, Spain, October 20 to 24, 2023. Highlights included promising advances for difficult-to-treat gastric, breast, and head and neck cancer, and a recent molecular genetics discovery.
MSK molecular geneticist Debyani Chakravarty, PhD, and colleagues analyzed the clinical actionability of more than 47,000 solid tumors.
What Proportion of Cancer Patients May Benefit from Precision Oncology? More Than You Think!
What proportion of cancer patients are eligible to benefit from precision oncology? There is an ongoing debate on this issue, partly due to a lack of consensus on which gene mutations are clinically actionable.
The Linear Accelerator (above), collects images to input into MSK's innovative 3D motion management platform.
MSK’s Motion Management Platform for Radiotherapy Reduces Late Urinary Toxicity in Prostate Cancer
An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared to a commercial image-guidance system, according to study results presented October 2 at the ASTRO 2023 Annual Meeting in San Diego.
The electronic nose (e-nose) is a promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK).
The E-Nose Knows: Can “Breathprint” Analysis Improve Accuracy in Lung Cancer Diagnosis?
There is a clear and unmet need for less invasive and more accurate methods for diagnosing lung cancer. A promising innovation under investigation at Memorial Sloan Kettering Cancer Center (MSK) is the electronic nose (e-nose), which evaluates volatile organic compounds (VOCs) in exhaled breath. The e-nose platform detects a lung cancer-associated “breathprint” in breath from individuals with lung cancer.